Genetics that protects your heart

A variant that decreases levels of bad fats is 40 times more common in an isolated Cretan population

Genetics that protects your heart

helic.jpg
Plot of HDL or 'good cholesterol' associated with the APOC3-R19X genetic variant

Researchers have found a key piece of the puzzle as to why an isolated population in Greece may live healthy lives. They have found that a genetic variant known to protect the heart is 40 times more common in this small Greek population than in other European populations.

The protective genetic variant, known as R19X, was first seen in the Amish population in 2008. This study demonstrates the same protective behaviour of the R19X variant and shows that the increased frequency of this variant is not just isolated to the Amish community.

The residents of Anogia and surrounding Mylopotamos villages live in mountainous villages on Crete. Anecdotally throughout Greece, these people are known to be strong and live long and healthy lives, despite a diet rich in animal fat that should cause health complications.

"The Mylopotamos villages residents have the same rate of diabetes as the general Greek population, but do not suffer from disease complications. Genetic studies like this can help us begin to understand why this is."

Professor Eleftheria Zeggini, lead author of the study from the Wellcome Trust Sanger Institute

The team, which includes collaborators at the Anogia Medical Centre and Harokopio University, took samples from more than 1,200 people living in Anogia and the surrounding villages (MANOLIS cohort). They then used DNA microchip technology to survey more thoroughly regions of the genome that have relatively rare variants that can disrupt protein function.

They found that R19X, a genetic variant in the gene APOC3, was far more common in this population than in other European populations. This variant decreases triglyceride levels, a blood fat that increases risk of heart disease, and increases levels of high density lipoproteins also known as 'good cholesterol', lowering risk of heart disease.

In other European populations, this R19X variant is found in 0.05 per cent of people. But in the MANOLIS cohort, it is found in two per cent of the population.

"Our work exemplifies the importance of studying these isolated populations. APOC3 is a gene that is relevant to all populations. This type of study can increase the pace of new therapeutic treatments against cardiovascular and metabolic disease."

Dr Ioanna Tachmazidou, first author from the Wellcome Trust Sanger Institute

Studying founder populations, or isolated populations, such as the MANOLIS cohort is extremely important. These populations empower the study and search of rare, clinically important genetic variants associated with complex disease. The MANOLIS cohort is named in honour of Manolis Giannakakis, 1978-2010.

Notes to Editors
Publications
  • A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates.

    Tachmazidou I, Dedoussis G, Southam L, Farmaki AE, Ritchie GR et al.

    Nature communications 2013;4;2872

Funding

This work was funded by the Wellcome Trust and the European Research Council.

Participating Centres
  • Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
  • Department of Dietetics-Nutrition, Harokopio, University of Athens, Athens 17671, Greece.
  • Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK.
  • European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, CB10 1SD, UK.
  • Department of Statistics, University of Oxford, Oxford OX1 3TG, UK.
  • Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland 21201-1595, USA.
  • Anogia Medical Centre, Anogia 74051, Greece.
Website
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

From childhood cancer to mapping human development: Pioneering scientist awarded 2019 Foulkes Foundation medal
Congratulations to Professor Muzlifah Haniffa, who has been recognised for her work on the immune system and childhood cancer
Dr Sam Behjati wins Liddy Shriver Early Career Research Award
Congratulations to Sanger Institute cancer researcher, Dr Sam Behjati, who has been recognised for his work in sarcoma cancer genomics
New malaria drug targets identified in liver stage of life cycle
Hope that new liver-stage drugs will help to counter the threat of antimicrobial resistance to current blood-stage medicines